This work was supported by National Natural Science Foundation of China (82004031) and Sichuan Science and Technology Program (2022NSFSC1303). We express our great appreciation to Jiayi Sun at Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, for the assistance with western blot.

1. Downloading the structures of xanthatin and Keap1
<ol>
	<li>Open the PubChem database (https://pubchem.ncbi.nlm.nih.gov/), input xanthatin (small molecule), then press&#160;Search and click on The First Result. Click on Download and click Save under 2D structure to save the compound in .sdf format.</li>
	<li>Download the crystal structure of the protein.
	<ol>
		<li>Open the UniProt database (https://www.uniprot.org/), input Keap1 and click on&#160;Search. Click Human under popular organisms in the left column, and then click on The First Entry Named Q14145 in the right column.</li>
		<li>Click on Structure under the function in the left column, find the structure with PDB ID: 2FLU, and click on RCSB-PDB. Click on Download Files and select PDB Format to download the crystal structure of Keap1 protein.</li>
	</ol>
	</li>
</ol>
2. Molecular docking
<ol>
	<li>Create a new folder named molecular docking on the desktop and save the downloaded xanthatin (small molecule) and Keap1 (protein) structures in this folder. 
	NOTE: Folder name and path must be in English.</li>
	<li>Open Maestro software, click File, select Change Working Directory, click Desktop, double-click to select the newly created molecular docking folder and click Choose Options.</li>
	<li>Small molecule processing
	<ol>
		<li>Click File and import structures options, click Desktop, double-click on molecular docking folder, click on xanthatin Structure File, and then click Open to import small molecule file.</li>
		<li>Click Tasks in the upper right corner of the software and select LigPrep option. Use structures from the workspace; the rest of the parameters are the default parameters and click Run to perform small molecule processing.</li>
	</ol>
	</li>
	<li>Protein structure processing
	<ol>
		<li>Click the File and Import Structures options, click Desktop, and double-click on the Molecular Docking folder. Click on the Keap1 Protein Structure file, and then click Open to import the protein structure file.</li>
		<li>Click Tasks in the upper right corner of the software and select the Protein Preparation Wizard option. Check the box Before Deleting Waters Beyond 5 &#197; From Het Groups and enter a pH of 7.4+/-0.0. Click Preprocess, click Refine, and then click Optimize &#62; Remove Waters &#62; Minimize.</li>
		<li>Click on the next task when the previous task is completed. Click Tasks and select the Sitemap option, use default settings for all parameters, and click Run.</li>
		<li>Click File and Import Structures options, click Desktop, double-click on the molecular docking folder, and open the folder named sitemap_1. Click on the first file named Sitemap_1_out.maegz, and then click Open.</li>
		<li>Double-click on the dot to select sitemap_1_protein in the workspace, and then click on Sitemap_1_site_1 to select it . Click Tasks and select the Receptor Grid Generation option. 
		NOTE: The protein sites predicted by the sitemap are ranked according to the scoring, with the highest-scoring site in the first place.</li>
		<li>Select the Entry option under receptor, with the remaining parameters unchanged. Click on the Small White Ball in the protein structure to generate a docking box of default size and change the job name to glide-grid_2FLU. Click Run.</li>
	</ol>
	</li>
	<li>Molecular docking
	<ol>
		<li>Click Tasks and select the Ligand Docking option. Select the Receptor Grid As from the file and click Browse. Click Desktop, double click on molecular docking folder, double click on glide-grid_2FLU file, click Glide-grid_2FLU.zip file, and then click Open.</li>
		<li>Click on Use Ligands From Files &#62; Browse &#62; Desktop. Double-click on the molecular docking folder, double-click on the ligprep_1 file, click Ligprep_1-out.maegz file, and then click Open.</li>
		<li>Click Settings and select Precision as XP (extra precision) option, change the job name to glide-dock_XP_2FLU, and click Run.</li>
	</ol>
	</li>
	<li>View docking results
	<ol>
		<li>Click File and Import Structures options, click Desktop, and double-click on the Molecular Docking folder. Double-click on the glide-dock_XP_2FLU file, click the glide-dock_XP_1_pv.maegz file and then click Open.</li>
		<li>Double-click on the dot to select ligand in the workspace, and then click to select sitemap_1_protein. Click Table, slide to the far right, and view the score under docking score.</li>
	</ol>
	</li>
	<li>Visualization of 2D results
	<ol>
		<li>Double click on the dot to select ligand in the workspace, and then click to also select sitemap_1_protein. Click Ligand Interaction &#62; View and check the LID legend box.</li>
		<li>Click File, choose Save Screenshot, input 6000 at the width, uncheck the box for Transparent Background, and click OK. Click on Desktop, name the file as 2D-xanthatin-2FLU, and save the image.</li>
	</ol>
	</li>
	<li>Visualization of 3D results
	<ol>
		<li>Double click on the dot to select ligand in the workspace, and then click to also select sitemap_1_protein.</li>
		<li>Click L in Quick Select to select small molecules, and then click Style. Click on the Second Line in the style to change the size of the small molecule bond and click on the color atoms to change the small molecule color.</li>
		<li>Select the small molecule in the figure, click the right mouse button, select Expand Selection, and choose 4 &#197;. Click Apply Labels in style to display the labels.</li>
		<li>Click on the second line in the style to change the size of amino acid bonds and click on the Color Atoms to change amino acid color.</li>
		<li>Click on Next &#62; Invert, hold down the control key and click on the first eye position under style to show only the amino acids with labels.</li>
		<li>Click on Style &#62; Ribbons to show the protein as a ribbon style and click on Edit Ribbon under ribbons to change the ribbon color.</li>
		<li>Click on Interactions Toggle in the bottom right corner of the screen, click the right mouse button and uncheck contacts/clashes.</li>
		<li>Search for measure in tasks, select Distance, and click on the two atoms connected by the yellow dotted line (hydrogen bond) in the screen to measure hydrogen bonds lengths.</li>
		<li>Press and hold the mouse&#39;s wheel to rotate the protein, adjust the protein to the center of the screen, and ensure that each amino acid label is visible.</li>
		<li>Click Workspace &#62; Save Image as and click on the desktop. Save the image as 600dpi by default, name the file as 3D-xanthatin-2FLU, choose file type as tiff format, and save the image.</li>
	</ol>
	</li>
</ol>
3. Cell culture and CETSA sample preparation
<ol>
	<li>Cell culture
	<ol>
		<li>Add 5 x 106 RAW264.7 cells/mL into a 100 mm culture dish and incubate with 6 mL of DMEM medium with 10% FBS and 1% antibiotic-antimycotic solution at 37 &#176;C, 95% humidity, and 5% CO2. Prepare three dishes and perform the experiment when the cells reach 80% confluency.</li>
	</ol>
	</li>
	<li>CETSA sample preparation
	<ol>
		<li>Aspirate the old medium, add 2 mL of phosphate buffer saline (PBS) warmed to room temperature to each dish, and wash 2x.</li>
		<li>Add 2 mL of PBS to each dish of cells, mix the cells, and collect cells into two 1.5 mL microcentrifuge tubes. Centrifuge at 377 x g for 3 min at room temperature.</li>
		<li>Discard the supernatant and resuspend cells with 2 mL of PBS containing 1% Broad-spectrum protease inhibitor mixtures. Divide into individual microcentrifuge tubes with 1 mL of cell suspension in each.</li>
		<li>Freeze microcentrifuge tubes in liquid nitrogen until white solid, then immediately thaw in a 37 &#176;C water bath and repeat 3x. Centrifuge at 12,000 x g at 4 &#176;C for 10 min.</li>
		<li>Take two microcentrifuge tubes, one with 100 &#181;M xanthatin and one with an equal volume of DMSO, and add 450 &#181;L of centrifuged supernatant to each tube, incubate at 37 &#176;C for 30 min.</li>
		<li>Add the supernatant from the two microcentrifuge tubes to 14 PCR tubes at a volume of 60 &#181;L/tube, and heat tubes simultaneously at varying temperatures (45 &#176;C, 48 &#176;C, 51 &#176;C, 54 &#176;C, 57 &#176;C, 60 &#176;C and 63 &#176;C) for 3 min, with two PCR tubes at each temperature, for the DMSO and xanthatin groups, respectively.</li>
		<li>For the unheated group, take supernatant from each of the two microcentrifuge tubes and add to 14 PCR tubes, 7 for the DMSO group and 7 for the xanthatin group, in a volume of 60 &#181;L each. Do not heat the samples here.</li>
		<li>Cool the tubes at room temperature for the heated group. Centrifuge all the tubes (heated and unheated) at 12,000 x g for 10 min at 4 &#176;C and take 48 &#181;L of supernatant from each tube to a new 1.5 mL microcentrifuge tube.Add 12 &#181;L of SDS-PAGE protein loading buffer to each tube, vortex to mix well, and heat in a water bath at 100 &#176;C for 5 min. 
		NOTE: Prepared CETSA samples must be stored at -80 &#176;C and tested by western blot within 1 week.</li>
	</ol>
	</li>
</ol>
4. Western blot
<ol>
	<li>Preparation of SDS-PAGE gel
	<ol>
		<li>Rinse one long and one short glass plate with ultrapure water. Place the plates into the clamping slot, then on a transparent board. Add ultrapure water and leak check for 10 min.</li>
		<li>Add 8 mL of lower gel solution and 8 mL of lower gel buffer into a conical flask and mix by gently shaking. Add 160 &#181;L of coagulant promoter to the gel solution and mix well. 
		NOTE: The volume of the lower layer of adhesive should not exceed the green line on the clamping slot.</li>
		<li>Drain the ultrapure water from the plates and blot them dry with filter paper. Add the prepared lower gel solution. Add 2 mL of isopropyl alcohol and wait for 20 min for solidification.</li>
		<li>Take 2 mL of upper gel solution and 2 mL of upper gel buffer into a conical flask and mix by gently shaking the flask.</li>
		<li>Remove the isopropyl alcohol from the gel layer and blot the excess isopropyl alcohol with filter paper.</li>
		<li>Add 40 &#181;L of coagulant promoter to the mixed upper gel solution, mix well, then add between the long and short glass plates and insert a 1.5 mm 15-hole comb, wait for 20 min. 
		NOTE: The comb should be inserted perpendicular to the upper layer, with no air bubbles between the comb and the solution.</li>
	</ol>
	</li>
	<li>Electrophoresis
	<ol>
		<li>Add 1 L of ultrapure water to a beaker, add a sachet of SDS-PAGE running buffer powder, stir well with a glass rod, and add the prepared gel to the electrophoresis unit. Place the unit in the box and pull out the comb.</li>
		<li>Thaw marker and CETSA samples at room temperature, vortex, and spin down. Add 2.5 &#181;L of marker to the first well and 20 &#181;L of CETSA samples to each of the remaining wells according to the predetermined sequence. 
		NOTE: CETSA samples were added successively according to temperature treatment described in step 3.2.6 from 45 &#176;C to 63 &#176;C; the DMSO group was added first, then the xanthatin group (Figure 1).</li>
		<li>Add the remaining electrophoresis solution to the electrophoresis unit, close the lid, and insert the electrode, positive pole to positive pole, negative pole to negative pole.</li>
		<li>Turn ON the power switch and adjust the voltage switch to 80 V to start electrophoresis.</li>
	</ol>
	</li>
	<li>Transfer to membrane
	<ol>
		<li>Add 850 mL of ultrapure water, 100 mL of anhydrous ethanol, and 50 mL of rapid transfer buffer to a beaker and stir well. Prepare foam board, plastic knives, tweezers, trays, and membrane transfer devices.</li>
		<li>Cut the PVDF membrane according to the size of the gel, mark it, and soak it in methanol for 30 s to activate it.</li>
		<li>Pour the transfer solution into the tray, place and open the transfer clamps, and place a sponge pad and three layers of transfer filter paper.</li>
		<li>Stop electrophoresis and then open the lid of the electrophoresis box. Take the electrophoresis device, pour out the electrophoresis solution, and remove the plate. Place the plate on the foam board, gently pry it off with a plastic knife, and cut the gel to clearly visualize the protein marker and the target proteins.</li>
		<li>Hold one side of the marker with tweezers, wash it in a tray containing the transmembrane solution, and lay it flat on filter paper. Dip the activated PVDF membrane into the transfer solution, hold the labeled side with tweezers, and cover the gel face-down. 
		NOTE: The PVDF membrane marked side is the front side and pay attention to the fact that no bubbles are generated during the placement process.</li>
		<li>Place two layers of transfer filter paper and one layer of sponge pad on the PVDF membrane, cover and clamp the transfer clips, and put them into the transfer tank. 
		NOTE: Black color of transfer clip to black color of transfer slot.</li>
		<li>Add the remaining transmembrane solution to the transmembrane cassette, cover with the lid, positive to positive, negative to negative.</li>
		<li>Adjust the current to 400 mA, time to 30 min, and then press Run to start transferring the membrane at room temperature.</li>
	</ol>
	</li>
	<li>Blocking
	<ol>
		<li>Add 2 L of ultrapure water to a glass vial, add a sachet of TBS powder, and then add 2 mL of Tween to make TBST solution. Weigh the BSA powder to prepare a 5% BSA solution with TBST and add 6 mL of BSA solution to the incubation box.</li>
		<li>Stop the membrane transfer and then open the transfer clip. Clamp the marker side of the PVDF membrane and place it in the incubation box. Place the incubation box on a shaker and block for 1.5 h at room temperature.</li>
	</ol>
	</li>
	<li>Incubation of primary antibody
	<ol>
		<li>Prepare the primary antibody (see Table of Materials for details) with 5% BSA solution at 1:1000, recycle the BSA solution in the incubator box, and add 6 mL of primary antibody to the incubation box. Place the incubation box in a foam box with ice packs and keep it on a shaker overnight.</li>
	</ol>
	</li>
	<li>Incubation of secondary antibody
	<ol>
		<li>Collect the primary antibody in the incubation box the next day, then add 6 mL of TBST solution and place it on a shaker to wash for 5 min.</li>
		<li>Pour off the washed TBST solution and add fresh for washing; repeat 5x and prepare the secondary antibody with 5% BSA solution at 1:5000.</li>
		<li>Pour off the TBST solution and add 6 mL of secondary antibody to the incubation box. Place the incubation box on a shaker and incubate for 1.5 h at room temperature.</li>
		<li>Collect the secondary antibody (see Table of Materials for details), then add 6 mL of TBST solution and place it on a shaker to wash for 5 min. Pour off the washed TBST solution and add fresh for washing; repeat 5x.</li>
	</ol>
	</li>
	<li>Exposing the strips
	<ol>
		<li>Retain the TBST solution at the end of the last wash. Take equal volumes of chemiluminescent reagents A and B, shake, and mix well. Shield the solution from light.</li>
		<li>Open the gel imaging system, click on Samples, check calibration, wait for calibration to complete, and then click on Marker, check calibration.</li>
		<li>Pick up the marker side of the strip with tweezers and fully immerse in the chemiluminescent reagent solution. Clamp one side of the marker to place the strip face down in the imager, close the lid of the imager, click on Exposure, and set the exposure time to 1 s. 
		NOTE: The developer must completely cover the strip, and the development should be in a dark environment.</li>
		<li>Click Save, name the image, and save it as a .tif file. Analyze the optical density of the western blot. The gray values of each temperature in the DMSO group were compared with the gray values of 45 &#176;C, and the gray values of each temperature in the xanthatin group were compared with the gray values of xanthatin at 45 &#176;C.</li>
	</ol>
	</li>
</ol>

Validating Xanthatin-Keap1 Interaction with Docking and CETSA

<ol>
	<li>Soleymani, F., Paquet, E., Viktor, H., Michalowski, W., Spinello, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Protein-protein+interaction+prediction+with+deep+learning:+A+comprehensive+review.">Protein-protein interaction prediction with deep learning: A comprehensive review.</a> Computat Struct Biotechnol J. 20, 5316-5341 (2022).</li><li>Du, X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Insights+into+protein-ligand+interactions:+mechanisms,+models,+and+methods.">Insights into protein-ligand interactions: mechanisms, models, and methods.</a> Int J Mol Sci. 17 (2), 144 (2016).</li><li>Wu, Q., Peng, Z., Zhang, Y., Yang, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=COACH-D:+improved+protein-ligand+binding+sites+prediction+with+refined+ligand-binding+poses+through+molecular+docking.">COACH-D: improved protein-ligand binding sites prediction with refined ligand-binding poses through molecular docking.</a> Nucleic Acids Res. 46, W438-W442 (2018).</li><li>Zhang, F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=PROBselect:+accurate+prediction+of+protein-binding+residues+from+proteins+sequences+via+dynamic+predictor+selection.">PROBselect: accurate prediction of protein-binding residues from proteins sequences via dynamic predictor selection.</a> Bioinfo. 36, i735-i744 (2020).</li><li>Kandel, J., Tayara, H., Chong, K. T. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=PUResNet:+prediction+of+protein-ligand+binding+sites+using+deep+residual+neural+network.">PUResNet: prediction of protein-ligand binding sites using deep residual neural network.</a> J Cheminfo. 13 (1), 65 (2021).</li><li>Dhakal, A., Mckay, C., Tanner, J. J., Cheng, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Artificial+intelligence+in+the+prediction+of+protein-ligand+interactions:+recent+advances+and+future+directions.">Artificial intelligence in the prediction of protein-ligand interactions: recent advances and future directions.</a> Brief Bioinform. 23 (1), 476 (2022).</li><li>Hatty, C. R., Banati, R. B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Protein-ligand+and+membrane-ligand+interactions+in+pharmacology:+the+case+of+the+translocator+protein+(TSPO).">Protein-ligand and membrane-ligand interactions in pharmacology: the case of the translocator protein (TSPO).</a> Pharmacol Res. 100, 58-63 (2015).</li><li>Chaires, J. B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Calorimetry+and+thermodynamics+in+drug+design.">Calorimetry and thermodynamics in drug design.</a> Ann Rev Biophys. 37, 135-151 (2008).</li><li>Huang, S. Y., Zou, X. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Advances+and+challenges+in+protein-ligand+docking.">Advances and challenges in protein-ligand docking.</a> Int J Mo Sci. 11 (8), 3016-3034 (2010).</li><li>Li, J., Fu, A., Zhang, L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=An+overview+of+scoring+functions+used+for+protein-ligand+interactions+in+molecular+docking.">An overview of scoring functions used for protein-ligand interactions in molecular docking.</a> Interdiscip Sci. 11 (2), 320-328 (2019).</li><li>Crampon, K., Giorkallos, A., Deldossi, M., Baud, S., Steffenel, L. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Machine-learning+methods+for+ligand-protein+molecular+docking.">Machine-learning methods for ligand-protein molecular docking.</a> Drug Discov Today. 27 (1), 151-164 (2022).</li><li>Pinzi, L., Rastelli, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Molecular+docking:+Shifting+paradigms+in+drug+discovery.">Molecular docking: Shifting paradigms in drug discovery.</a> Int J Mol Sci. 20 (18), 4331 (2019).</li><li>Abdolmaleki, A., Ghasemi, F., Ghasemi, J. B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Computer-aided+drug+design+to+explore+cyclodextrin+therapeutics+and+biomedical+applications.">Computer-aided drug design to explore cyclodextrin therapeutics and biomedical applications.</a> Chem Biol Drug Des. 89 (2), 257-268 (2017).</li><li>Chen, G., Seukep, A. J., Guo, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Recent+advances+in+molecular+docking+for+the+research+and+discovery+of+potential+marine+drugs.">Recent advances in molecular docking for the research and discovery of potential marine drugs.</a> Mar Drugs. 18 (11), 545 (2020).</li><li>Li, T., Guo, R., Zong, Q., Ling, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Application+of+molecular+docking+in+elaborating+molecular+mechanisms+and+interactions+of+supramolecular+cyclodextrin.">Application of molecular docking in elaborating molecular mechanisms and interactions of supramolecular cyclodextrin.</a> Carbohydr Polym. 276, 118644 (2022).</li><li>Martinez Molina, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Monitoring+drug+target+engagement+in+cells+and+tissues+using+the+cellular+thermal+shift+assay.">Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay.</a> Science. 341 (6141), 84-87 (2013).</li><li>Tu, Y., Tan, L., Tao, H., Li, Y., Liu, H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=CETSA+and+thermal+proteome+profiling+strategies+for+target+identification+and+drug+discovery+of+natural+products.">CETSA and thermal proteome profiling strategies for target identification and drug discovery of natural products.</a> Phytomedicine. 116, 154862 (2023).</li><li>Dai, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Horizontal+cell+biology:+Monitoring+global+changes+of+protein+interaction+states+with+the+proteome-wide+cellular+thermal+shift+assay+(CETSA).">Horizontal cell biology: Monitoring global changes of protein interaction states with the proteome-wide cellular thermal shift assay (CETSA).</a> Annu Rev Biochem. 88, 383-408 (2019).</li><li>Lade, D. M., Nicoletti, R., Mersch, J., Agazie, Y. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Design+and+synthesis+of+improved+active-site+SHP2+inhibitors+with+anti-breast+cancer+cell+effects.">Design and synthesis of improved active-site SHP2 inhibitors with anti-breast cancer cell effects.</a> Eur J Med Chem. 247, 115017 (2023).</li><li>Jiang, X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Novel+chemical-structure+TPOR+agonist,+TMEA,+promotes+megakaryocytes+differentiation+and+thrombopoiesis+via+mTOR+and+ERK+signalings.">Novel chemical-structure TPOR agonist, TMEA, promotes megakaryocytes differentiation and thrombopoiesis via mTOR and ERK signalings.</a> Phytomedicine. 110, 154637 (2023).</li><li>Mateus, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Thermal+proteome+profiling+for+interrogating+protein+interactions.">Thermal proteome profiling for interrogating protein interactions.</a> Mol Syst Biol. 16 (3), 9232 (2020).</li><li>Sanchez, T. W., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Real-time+cellular+thermal+shift+assay+to+monitor+target+engagement.">Real-time cellular thermal shift assay to monitor target engagement.</a> ACS Chem Biol. 17 (9), 2471-2482 (2022).</li><li>Tolvanen, T. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Current+advances+in+CETSA.">Current advances in CETSA.</a> Front Mol Biosci. 9, 866764 (2022).</li><li>Liu, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Xanthatin+inhibits+STAT3+and+NF-&#954;B+signalling+by+covalently+binding+to+JAK+and+IKK+kinases.">Xanthatin inhibits STAT3 and NF-&#954;B signalling by covalently binding to JAK and IKK kinases.</a> J Cell Mol Med. 23 (6), 4301-4312 (2019).</li><li>Liu, Y., Chen, W., Zheng, F., Yu, H., Wei, K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Xanthatin+alleviates+LPS-Induced+inflammatory+response+in+RAW264.7+macrophages+by+Inhibiting+NF-&#954;B,+MAPK+and+STATs+activation.">Xanthatin alleviates LPS-Induced inflammatory response in RAW264.7 macrophages by Inhibiting NF-&#954;B, MAPK and STATs activation.</a> Molecules. 27 (14), 4603 (2022).</li><li>Dinkova-Kostova, A. T., Kostov, R. V., Canning, P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Keap1,+the+cysteine-based+mammalian+intracellular+sensor+for+electrophiles+and+oxidants.">Keap1, the cysteine-based mammalian intracellular sensor for electrophiles and oxidants.</a> Arch Biochem Biophys. 617, 84-93 (2017).</li><li>Tabana, Y., Babu, D., Fahlman, R., Siraki, A. G., Barakat, K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Target+identification+of+small+molecules:+An+overview+of+the+current+applications+in+drug+discovery.">Target identification of small molecules: An overview of the current applications in drug discovery.</a> BMC Biotechnol. 23 (1), 44 (2023).</li><li>Schenone, M., Dan&#269;&#237;k, V., Wagner, B. K., Clemons, P. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Target+identification+and+mechanism+of+action+in+chemical+biology+and+drug+discovery.">Target identification and mechanism of action in chemical biology and drug discovery.</a> Nat Chem Biol. 9 (4), 232-240 (2013).</li><li>Hughes, J. P., Rees, S., Kalindjian, S. B., Philpott, K. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Principles+of+early+drug+discovery.">Principles of early drug discovery.</a> Br J Pharmacol. 162 (6), 1239-1249 (2011).</li><li>Chakraborty, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=SARS-CoV-2+protein+drug+targets+landscape:+A+potential+pharmacological+insight+view+for+the+new+drug+development.">SARS-CoV-2 protein drug targets landscape: A potential pharmacological insight view for the new drug development.</a> Expert Rev Clin Pharmacol. 14 (2), 225-238 (2021).</li><li>Ziegler, S., Pries, V., Hedberg, C., Waldmann, H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Target+identification+for+small+bioactive+molecules:+Finding+the+needle+in+the+haystack.">Target identification for small bioactive molecules: Finding the needle in the haystack.</a> Angew Chem Int Ed Engl. 52 (10), 2744-2792 (2013).</li><li>Zhang, X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Highly+effective+identification+of+drug+targets+at+the+proteome+level+by+pH-dependent+protein+precipitation.">Highly effective identification of drug targets at the proteome level by pH-dependent protein precipitation.</a> Chem Sci. 13 (42), 12403-12418 (2022).</li><li>Zhang, X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+simplified+thermal+proteome+profiling+approach+to+screen+protein+targets+of+a+ligand.">A simplified thermal proteome profiling approach to screen protein targets of a ligand.</a> Proteomics. 20, 1900372 (2020).</li><li>Hou, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Salidroside+intensifies+mitochondrial+function+of+CoCl2-damaged+HT22+cells+by+stimulating+PI3K-AKT-MAPK+signaling+pathway.">Salidroside intensifies mitochondrial function of CoCl2-damaged HT22 cells by stimulating PI3K-AKT-MAPK signaling pathway.</a> Phytomedicine. 109, 154568 (2022).</li><li>Wang, X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Salidroside,+a+phenyl+ethanol+glycoside+from+Rhodiolacrenulata,+orchestrates+hypoxic+mitochondrial+dynamics+homeostasis+by+stimulating+Sirt1/p53/Drp1+signaling.">Salidroside, a phenyl ethanol glycoside from Rhodiolacrenulata, orchestrates hypoxic mitochondrial dynamics homeostasis by stimulating Sirt1/p53/Drp1 signaling.</a> J Ethnopharmacol. 293, 115278 (2022).</li></ol>

The authors have nothing to disclose.

The identification of disease targets and the discovery and development of drugs are closely interconnected27. By precisely targeting specific targets, drug candidates can be developed to treat particular diseases more effectively while concurrently minimizing the side effects associated with the drugs28,29. The most commonly used targets are protein targets30. However, the identification of special protein targets ...

Proteins are highly important macromolecules in living organisms and possess a diverse range of unique functions within cells, such as membrane composition, cytoskeleton formation, enzyme activity, transportation, cell signaling, and involvement in both intracellular and extracellular mechanisms1,2,3. Proteins manifest their biological functions primarily through specific interactions with a variety of molecules, including other proteins, nucleic acids, small molecule ligands, and metal ions1,4. Ligands are small molecular compounds that specifically bind to proteins in an organism. The interaction between proteins and ligands occurs at specific sites on the protein, called the binding sites, also known as the binding pockets5. In medicinal chemistry research, the focus lies in identifying key proteins that are clearly associated with diseases, which serve as targets for drugs6. Therefore, gaining a deep understanding of the binding sites between proteins and ligands is of utmost importance in promoting drug discovery, design, and research7,8.
Molecular docking is a widely used computational tool for studying protein-ligand binding, which employs the three-dimensional structures of proteins and ligands to explore their primary binding modes and affinities when forming stable complexes9,10,11. The application of molecular docking technology originated in the 1970s. Based on the lock and key pairing principle and utilizing the algorithms of molecular docking software, one can determine the interaction between compounds and molecular targets by analyzing docking results. This approach enables the prediction of active binding sites for both the compound and the target molecule. Consequently, it facilitates the identification of an optimal binding conformation (here called the binding model) for ligand-receptor interactions, which is crucial for understanding the mechanics of these molecular engagements12,13,14,15. While molecular docking provides valuable computer-based predictions of ligand-receptor interactions, it is important to note that these are preliminary findings. Consequently, further experimental verification is essential to confirm these interactions.
The cellular thermal shift assay (CETSA), initially proposed by P&#228;r Nordlund&#39;s research team in 2013, serves as a method for validating drug-target protein interactions. This technique specifically tests the thermal stability of target proteins induced by drug binding, providing a practical approach for confirming molecular interactions16,17,18. This approach is based on the fundamental principle that ligand binding initiates a thermal shift within target proteins and is applicable to a wide array of biological samples, including cell lysates, intact living cells, and tissues19,20. CETSA supports direct target engagement of small molecules in intact cells by detecting thermodynamic stabilization of proteins due to ligand binding and linking the observed phenotypic response to the target compound21,22. Among the various methodologies derived from CETSA, Western Blot-CETSA (WB-CETSA) is considered a classical approach. Following sample preparation using the CETSA method, western blot analysis is utilized to detect alterations in the thermal stability of the target protein. This allows for the precise determination of drug-protein interactions within cellular systems17,23.
Xanthatin is a bioactive compound isolated from the plant Xanthium L. with properties such as anti-inflammatory, which has been used in traditional Chinese medicine to treat diseases like nasal sinusitis and arthritis24,25. The kelch-like ECH-associated protein 1 (Keap1) is a component of the Cullin3-based Cullin-RING E3 ubiquitin ligase multi-subunit protein complex and an important regulator of intracellular redox homeostasis, which influences the intensity and duration of the inflammatory response by modulating the intracellular redox state26. In this study, we first utilized molecular docking to investigate the interaction between xanthatin (small molecule) and Keap1 protein, aiming to predict their binding mode. Subsequently, we employed the CETSA method to validate this interaction by assessing the impact of xanthatin on the thermal stability of the Keap1 protein.

<table><tbody><tr><td>0.45 &amp;mu;m Polyvinylidene fluoride membrane</td><td>Millipore</td><td>PR05509</td><td></td></tr><tr><td>Anhydrous ethanol</td><td>Chron chemicals</td><td>64-17-5</td><td></td></tr><tr><td>Bovine serum albumin</td><td>BioFroxx</td><td>4240GR100</td><td></td></tr><tr><td>Broad-spectrum protease inhibitor mixtures</td><td>Boster Biological Technology Co., Ltd</td><td>AR1193</td><td></td></tr><tr><td>DMSO</td><td>Boster Biological Technology Co., Ltd</td><td>PYG0040</td><td></td></tr><tr><td>Enhanced chemiluminescence reagent</td><td>Beyotime Biotechnology Co., Ltd</td><td>P0018S</td><td></td></tr><tr><td>GAPDH antibody</td><td>ProteinTech Group Co., Ltd</td><td>10494-1-AP</td><td></td></tr><tr><td>Gel Imaging Instrument</td><td>E-BLOT</td><td>Touch Imager Pro</td><td></td></tr><tr><td>Gradient PCR instrument</td><td>Biometra TADVANCED</td><td>Biometra Tadvanced 96SG</td><td></td></tr><tr><td>High-speed freezing centrifuge</td><td>Beckman Coulter</td><td>Allegra X-30R</td><td></td></tr><tr><td>Horseradish peroxidase-conjugated affiniPure goat antibody</td><td>ProteinTech Group Co., Ltd</td><td>SA00001-2</td><td></td></tr><tr><td>Isopropyl alcohol&amp;nbsp;</td><td>Chron chemicals</td><td>67-63-0</td><td></td></tr><tr><td>Keap1 antibody</td><td>Zen BioScience Co., Ltd</td><td>R26935</td><td></td></tr><tr><td>Metal bath</td><td>Analytik Jena</td><td>TSC</td><td></td></tr><tr><td>Methanol</td><td>Chron chemicals</td><td>67-56-1</td><td></td></tr><tr><td>Ncmblot rapid transfer buffer (20&amp;times;)</td><td>NCM Biotech Co., Ltd</td><td>WB4600</td><td></td></tr><tr><td>Omni-Easy OneStep PAGE gel fast preparation kie</td><td>Epizyme Biotech Co., Ltd</td><td>PG212</td><td></td></tr><tr><td>Phosphate buffer saline</td><td>Boster Biological Technology Co., Ltd</td><td>PYG0021</td><td></td></tr><tr><td>Prestained Color Protein Marker</td><td>Biosharp&amp;nbsp;</td><td>BL741A</td><td></td></tr><tr><td>Protein Blotting Electrophoresis System</td><td>Bio-Rad</td><td>MiniPROTEAN&amp;Ograve;Tetra Cell</td><td></td></tr><tr><td>RAW264.7 cell</td><td>Beyotime Biotechnology Co., Ltd</td><td>C7505</td><td></td></tr><tr><td>RAW264.7 cell-specific medium</td><td>Procell Life Science&amp;amp;Technology Co., Ltd</td><td>CM-0597</td><td></td></tr><tr><td>SDS-PAGE protein loading buffer</td><td>Boster Biological Technology Co., Ltd</td><td>AR1112-10</td><td></td></tr><tr><td>SDS-PAGE running buffer powder</td><td>Servicebio</td><td>G2018</td><td></td></tr><tr><td>Tris buffered saline powder</td><td>Servicebio</td><td>G0001</td><td></td></tr><tr><td>Tween 20</td><td>BioFroxx</td><td>1247ML100</td><td></td></tr><tr><td>Water bath</td><td>Memmert</td><td>WNE10</td><td></td></tr><tr><td>Water purifier</td><td>Millipore</td><td>Milli- IQ 7005</td><td></td></tr><tr><td>Xanthatin</td><td>ChemConst Biotechnology Co., Ltd</td><td>CONST210706</td><td></td></tr></tbody></table>

protein target prediction and validation of small molecule compound

Proteins are fundamental to human physiology, with their targets being crucial in research and drug development. The identification and validation of crucial protein targets have become integral to drug development. Molecular docking is a computational tool widely utilized to investigate protein-ligand binding, especially in the context of drug and protein target interactions. For the experimental verification of the binding and to access the binding of the drug and its target directly, the cellular thermal shift assay (CETSA) method is used. This study aimed to integrate molecular docking with CETSA to predict and validate interactions between drugs and vital protein targets. Specifically, we predicted the interaction between xanthatin and Keap1 protein as well as its binding mode through molecular docking analysis, followed by verification of the interaction using the CETSA assay. Our results demonstrated that xanthatin could establish hydrogen bonds with specific amino acid residues of Keap1 protein and reduce the thermostability of Keap1 protein, indicating that xanthatin could directly interact with Keap1 protein.

Molecular docking analysis predicted the interaction between xanthatin and Keap1 protein. Figure 2 demonstrates the formation of hydrogen bonds between xanthatin and amino acid residues Gly-367 and Val-606 of Keap1 protein, with a hydrogen bond length of 2.17 &#197; for Gly-367 and 2.13 &#197; for Val-606. In addition, the calculated docking score of -5.69 kcal/mol signifies a good binding affinity between xanthatin and Keap1 protein.
The CETSA method showed that ...

Watch this Scientific Journal Video about Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA at JoVE.com

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

The experiment used here shows a method of molecular docking combined with cellular thermal shift assay to predict and validate the interaction between small molecules and protein targets.

Protein Target Prediction and Validation of Small Molecule Compound

Proteins are fundamental to human physiology, with their targets being crucial in research and drug development. The identification and validation of ...

protein-target-prediction-and-validation-of-small-molecule-compound

Research

JoVE Journal

Medicine

2.2K Views.  Chengdu University of Traditional Chinese Medicine. The experiment used here shows a method of molecular docking combined with cellular thermal shift assay to predict and validate the interaction between small molecules and protein targets.

Video: Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Identification of Small Molecule-binding Proteins in a Native Cellular Environment by Live-cell Photoaffinity Labeling

Identifying the molecular target(s) of small molecules is a challenging but necessary step towards understanding their mechanism of action. While several target identification methods have been developed and used to successfully elucidate the binding proteins of a variety of small molecules, these techniques have drawbacks that make them unsuitable for detecting certain types of small molecule-target interactions. In particular, non-covalent interactions that depend on native cellular conditions, such as those of membrane proteins whose structures may be perturbed upon cell lysis, are often not amenable to affinity-based target identification methods. Here, we demonstrate a method wherein a probe containing a photolabile group is used to covalently crosslink to the small molecule binding protein within the environment of the live cell, allowing the detection and isolation of the target protein without the need for maintenance of the interaction after cell lysis. This technique is a valuable tool for studying biologically interesting small molecules with unknown mechanisms, both in the context of basic biology as well as drug discovery.

We describe here a method for identification of small molecule-binding proteins using photoaffinity labeling. The advantage of this technique is that binding and covalent labeling of the target proteins occurs within the live cellular environment, removing the risk of disrupting native protein structure and binding conditions upon cell lysis.

Identifying the molecular target(s) of small molecules is a challenging but necessary step towards understanding their mechanism of action. While several ...

Biochemistry

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels are expressed ubiquitously throughout the brain, where they function to regulate the excitability of neurons. The subcellular distribution of these channels in pyramidal neurons of hippocampal area CA1 is regulated by tetratricopeptide repeat-containing Rab8b interacting protein (TRIP8b), an auxiliary subunit. Genetic knockout of HCN pore forming subunits or TRIP8b, both lead to an increase in antidepressant-like behavior, suggesting that limiting the function of HCN channels may be useful as a treatment for Major Depressive Disorder (MDD). Despite significant therapeutic interest, HCN channels are also expressed in the heart, where they regulate rhythmicity. To circumvent off-target issues associated with blocking cardiac HCN channels, our lab has recently proposed targeting the protein-protein interaction between HCN and TRIP8b in order to specifically disrupt HCN channel function in the brain. TRIP8b binds to HCN pore forming subunits at two distinct interaction sites, although here the focus is on the interaction between the tetratricopeptide repeat (TPR) domains of TRIP8b and the C terminal tail of HCN1. In this protocol, an expanded description of a method for purifying TRIP8b and executing a high throughput screen to identify small molecule inhibitors of the interaction between HCN and TRIP8b, is described. The method for high throughput screening utilizes a Fluorescence Polarization (FP) -based assay to monitor the binding of a large TRIP8b fragment to a fluorophore-tagged eleven amino acid peptide corresponding to the HCN1 C terminal tail. This method allows &#39;hit&#39; compounds to be identified based on the change in the polarization of emitted light. Validation assays are then performed to ensure that &#39;hit&#39; compounds are not artifactual.

The interaction between HCN channels and their auxiliary subunit has been identified as a therapeutic target in Major Depressive Disorder. Here, a fluorescence polarization-based method for identifying small molecule inhibitors of this protein-protein interaction, is presented.

Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels are expressed ubiquitously throughout the brain, where they function to regulate the ...

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Drug Affinity Responsive Target Stability (DARTS) is a robust method for detection of novel small molecule protein targets. It can be used to verify known small molecule-protein interactions and to find potential protein targets for natural products. Compared with other methods, DARTS uses native, unmodified, small molecules and is simple and easy to operate. In this study, we further enhanced the data analysis capabilities of the DARTS experiment by monitoring the changes in protein stability and estimating the affinity of protein-ligand interactions. The protein-ligand interactions can be plotted into two curves: a proteolytic curve and a dose-dependence curve. We have used the mTOR-rapamycin interaction as an exemplary case for establishment of our protocol. From the proteolytic curve we saw that the proteolysis of mTOR by pronase was inhibited by the presence of rapamycin. The dose-dependency curve allowed us to estimate the binding affinity of rapamycin and mTOR. This method is likely to be a powerful and simple method for accurately identifying novel target proteins and for the optimization of drug target engagement.

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

In this study, we enhanced the data analysis capabilities of the DARTS experiment by monitoring the changes in protein stability and estimating the affinity of protein-ligand interactions. The interactions can be plotted into two curves: a proteolytic curve and a dose-dependence curve. We have used mTOR-rapamycin interaction as an exemplary case.

Drug Affinity Responsive Target Stability (DARTS) is a robust method for detection of novel small molecule protein targets. It can be used to verify known ...

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Targeted protein degradation compounds, including molecular glues or proteolysis targeting chimeras, are an exciting new therapeutic modality in small molecule drug discovery. This class of compounds induces protein degradation by bringing into proximity the target protein and the E3 ligase machinery proteins required to ubiquitinate and ultimately degrade the target protein through the ubiquitin-proteasomal pathway (UPP). Profiling of target protein degradation in a high-throughput fashion, however, remains highly challenging given the complexity of cellular pathways required to achieve degradation. Here we present a protocol and screening strategy based on the use of CRISPR/Cas9 endogenous tagging of target proteins with the 11 amino acid HiBiT tag which complements with high affinity to the LgBiT protein, to produce a luminescent protein. These CRISPR targeted cell lines with endogenous tags can be used to measure compound induced degradation in either real-time, kinetic live cell or endpoint lytic modes by monitoring luminescent signal using a luminescent plate-based reader. Here we outline the recommended screening protocols for the different formats, and&#160;also describe the calculation of key degradation parameters of rate, Dmax, DC50, Dmax50, as well as multiplexing with cell viability assays. These approaches enable rapid discovery and triaging of early stage compounds while maintaining endogenous expression and regulation of target proteins in relevant cellular backgrounds, allowing for efficient optimization of lead therapeutic compounds.

This protocol describes the quantitative luminescent detection of protein degradation kinetics in living cells that have been engineered using CRISPR/Cas9 to express antibody free endogenous protein detection tag fused to a target protein. Detailed instructions for calculating and obtaining quantitative degradation parameters, rate, Dmax, DC50, and Dmax50 are included.

Targeted protein degradation compounds, including molecular glues or proteolysis targeting chimeras, are an exciting new therapeutic modality in small ...

Cancer Research

A Rapid and Quantitative Fluorimetric Method for Protein-Targeting Small Molecule Drug Screening

We demonstrate a new drug screening method for determining the binding affinity of small drug molecules to a target protein by forming fluorescent gold nanoclusters (Au NCs) within the drug-loaded protein, based on the differential fluorescence signal emitted by the Au NCs. Albumin proteins such as human serum albumin (HSA) and bovine serum albumin (BSA) are selected as the model proteins. Four small molecular drugs (e.g., ibuprofen, warfarin, phenytoin, and sulfanilamide) of different binding affinities to the albumin proteins are tested. It was found that the formation rate of fluorescent Au NCs inside the drug loaded albumin protein under denaturing conditions (i.e., 60 &#176;C or in the presence of urea) is slower than that formed in the pristine protein (without drugs). Moreover, the fluorescent intensity of the as-formed NCs is found to be inversely correlated to the binding affinities of these drugs to the albumin proteins. Particularly, the higher the drug-protein binding affinity, the slower the rate of Au NCs formation, and thus a lower fluorescence intensity of the resultant Au NCs is observed. The fluorescence intensity of the resultant Au NCs therefore provides a simple measure of the relative binding strength of different drugs tested. This method is also extendable to measure the specific drug-protein binding constant (KD) by simply varying the drug content preloaded in the protein at a fixed protein concentration. The measured results match well with the values obtained using other prestige but more complicated methods.

A protocol for small molecular drug screening based on in-situ synthesis of ultrasmall fluorescent gold nanoclusters (Au NCs) using drug-loaded protein as template is presented. This method is simple to determine the binding affinity of drugs to a target protein by a visible fluorescent signal emitted from the protein-templated Au NCs.

We demonstrate a new drug screening method for determining the binding affinity of small drug molecules to a target protein by forming fluorescent gold ...

Bioengineering

Predicting Amino Acid Preferences of Protein-Protein Binding Interfaces

Computational Prediction of Amino Acid Preferences of Potentially Multispecific Peptide-Binding Domains Involved in Protein-Protein Interactions

Many protein-protein interactions involve the binding of short protein segments to peptide-binding domains. Usually, such interactions require the recognition of linear motifs with variable conservation. The combination of highly conserved and more variable regions in the same ligands often contributes to the multispecificity of binding, a common property of enzymes and cell signaling proteins. Characterization of amino acid preferences of peptide-binding domains is important for the design of mediators of protein-protein interactions (PPIs). Computational methods are an efficient alternative to the often costly and cumbersome experimental techniques, enabling the design of potential mediators that can be later validated in downstream experiments. Here, we described a methodology using the Pepspec application of the Rosetta molecular modeling package to predict the amino acid preferences of peptide-binding domains. This methodology is useful when the structure of the receptor protein and the nature of the peptide ligand are both known or can be inferred. The methodology starts with a well-characterized anchor from the ligand, which is extended by randomly adding amino acid residues. The binding affinity of peptides generated this way is then evaluated by flexible-backbone peptide docking in order to select the peptides with the best predicted binding scores. These peptides are then used to calculate amino acid preferences and to optionally compute a position-weight matrix (PWM) that can be used in further studies. To illustrate the application of this methodology, we used the interaction between subunits of human interferon regulatory factor 5 (IRF5), previously known to be multispecific but globally guided by a short conserved motif called pLxIS. The estimated amino acid preferences were consistent with previous knowledge about the IRF5 binding surface. Positions occupied by phosphorylatable serine residues exhibited a high frequency of aspartate and glutamate, likely because their negatively charged side chains are similar to phosphoserine.

Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions

We describe a methodology based on sequence diversification to estimate the amino acid preferences of multispecific binding sites in protein-protein interactions (PPIs). In this strategy, thousands of potential peptide ligands are generated and screened in silico, thus overcoming some limitations of available experimental methods.

Many protein-protein interactions involve the binding of short protein segments to peptide-binding domains. Usually, such interactions require the ...

A Protocol for Computer-Based Protein Structure and Function Prediction

Genome sequencing projects have ciphered millions of protein sequence, which require knowledge of their structure and function to improve the understanding of their biological role. Although experimental methods can provide detailed information for a small fraction of these proteins, computational modeling is needed for the majority of protein molecules which are experimentally uncharacterized. The I-TASSER server is an on-line workbench for high-resolution modeling of protein structure and function. Given a protein sequence, a typical output from the I-TASSER server includes secondary structure prediction, predicted solvent accessibility of each residue, homologous template proteins detected by threading and structure alignments, up to five full-length tertiary structural models, and structure-based functional annotations for enzyme classification, Gene Ontology terms and protein-ligand binding sites. All the predictions are tagged with a confidence score which tells how accurate the predictions are without knowing the experimental data. To facilitate the special requests of end users, the server provides channels to accept user-specified inter-residue distance and contact maps to interactively change the I-TASSER modeling; it also allows users to specify any proteins as template, or to exclude any template proteins during the structure assembly simulations. The structural information could be collected by the users based on experimental evidences or biological insights with the purpose of improving the quality of I-TASSER predictions. The server was evaluated as the best programs for protein structure and function predictions in the recent community-wide CASP experiments. There are currently &gt;20,000 registered scientists from over 100 countries who are using the on-line I-TASSER server.

Guidelines for computer based structural and functional characterization of protein using the I-TASSER pipeline is described. Starting from query protein sequence, 3D models are generated using multiple threading alignments and iterative structural assembly simulations. Functional inferences are thereafter drawn based on matches to proteins with known structure and functions.

Genome sequencing projects have ciphered millions of protein sequence, which require knowledge of their structure and function to improve the ...

Biology

Quantitative-Irreversible Tethering: Screening Electrophilic Ligands Efficiently

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay

Compounds that form covalent bonds with specific target proteins offer a variety of advantages&#160;as chemical probes and therapeutic agents. Most commonly, mildly reactive, electrophilic small molecules are employed to form covalent bonds with select cysteine side chains in specific proteins. Electrophile-first approaches of ligand discovery, whereby a library of electrophilic small molecules are screened against a protein target, have become popular as they avoid the need for time-consuming downstream installation of an electrophilic warhead. Such screening is complicated, however, as electrophilic ligands can exhibit a wide range of different rates of spontaneous reaction with cysteines. Quantitative-irreversible tethering (qIT) offers a fluorescence-based method for hit identification and development that normalizes data for these differences in intrinsic compound reactivity. Rates of reaction of individual compounds with a target protein are determined and compared to compound reactivity with the unstructured tripeptide glutathione (this being a proxy for spontaneous compound reaction), enabling the identification of compounds that preferentially react with the protein of interest. This methodology has been successfully applied to identify selective covalent fragments against several drug targets, including SARS-CoV-2 main protease, cyclin-dependent kinase 2, and RAP27A. Here, we demonstrate the application of qIT to a target protein to generate a quantitative and robust data set, allowing prioritization of hit ligands for future development.

The quantitative irreversible tethering (qIT) assay is a fluorescence-based method of identifying covalent fragments that selectively engage with a target protein. Here, a detailed protocol is outlined to describe the qIT assay, with example results included.

Compounds that form covalent bonds with specific target proteins offer a variety of advantages&#160;as chemical probes and therapeutic agents. Most ...

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Receptors and enzyme proteins are important biomolecules that act as binding targets for bioactive small molecules. Thus, the rapid and global validation of the drug-protein interactions is highly desirable for not only understanding the molecular mechanisms underlying therapeutic efficacy but also for assessing drug characteristics, such as adsorption, distribution, metabolism, excretion, and toxicity (ADMET) for clinical use. Here, we present a biosensor-based high throughput strategy for the biopanning of T7 phage-displayed short peptides that can be easily displayed on the phage capsid. Subsequent analysis of the amino acid sequences of peptides containing short segments, as &#34;broken relics&#34;, of the drug-binding sites using bioinformatics programs in receptor ligand contact (RELIC) suite, is also shown. By applying this method to two clinically approved drugs, an anti-tumor irinotecan, and an anti-flu oseltamivir, the detailed process for collecting the drug-recognizing peptide sequences and highlighting the drug-binding sites of the target proteins are explained in this paper. The strategy described herein can be applied for any small molecules of interest.

This study aimed to present a strategy for identifying drug-peptide interactions. The strategy involves the biopanning of drug-recognizing short peptides based on a quartz-crystal microbalance (QCM) biosensor, followed by bioinformatics analysis for quantitatively assessing the information obtained for the drug recognition and annotation of the drug-binding sites on proteins.

Receptors and enzyme proteins are important biomolecules that act as binding targets for bioactive small molecules. Thus, the rapid and global validation ...

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

The aim of de novo protein design is to find the amino acid sequences that will fold into a desired 3-dimensional structure with improvements in specific properties, such as binding affinity, agonist or antagonist behavior, or stability, relative to the native sequence. Protein design lies at the center of current advances drug design and discovery. Not only does protein design provide predictions for potentially useful drug targets, but it also enhances our understanding of the protein folding process and protein-protein interactions. Experimental methods such as directed evolution have shown success in protein design. However, such methods are restricted by the limited sequence space that can be searched tractably. In contrast, computational design strategies allow for the screening of a much larger set of sequences covering a wide variety of properties and functionality. We have developed a range of computational de novo protein design methods capable of tackling several important areas of protein design. These include the design of monomeric proteins for increased stability and complexes for increased binding affinity.
To disseminate these methods for broader use we present Protein WISDOM (<a href="http://www.proteinwisdom.org" target="_blank">http://www.proteinwisdom.org</a>), a tool that provides automated methods for a variety of protein design problems. Structural templates are submitted to initialize the design process. The first stage of design is an optimization sequence selection stage that aims at improving stability through minimization of potential energy in the sequence space. Selected sequences are then run through a fold specificity stage and a binding affinity stage. A rank-ordered list of the sequences for each step of the process, along with relevant designed structures, provides the user with a comprehensive quantitative assessment of the design. Here we provide the details of each design method, as well as several notable experimental successes attained through the use of the methods.

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

We developed computational de novo protein design methods capable of tackling several important areas of protein design. To disseminate these methods we present Protein WISDOM, an online tool for protein design (<a href="http://www.proteinwisdom.org" target="_blank">http://www.proteinwisdom.org</a>). Starting from a structural template, design of monomeric proteins for increased stability and complexes for increased binding affinity can be performed.

The aim of de novo protein design is to find the amino acid sequences that will fold into a desired 3-dimensional structure with improvements in specific ...

Protein Target Prediction and Validation of Small Molecule Compound

Summary

Explore More Videos

Chapters in this video

Identification of Small Molecule-binding Proteins in a Native Cellular Environment by Live-cell Photoaffinity Labeling

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

A Rapid and Quantitative Fluorimetric Method for Protein-Targeting Small Molecule Drug Screening

Computational Prediction of Amino Acid Preferences of Potentially Multispecific Peptide-Binding Domains Involved in Protein-Protein Interactions

A Protocol for Computer-Based Protein Structure and Function Prediction

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules